Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12456653
Chiu CW, et al. (2002) BLNK: molecular scaffolding through 'cis'-mediated organization of signaling proteins. EMBO J 21, 6461-72 12456653
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y72-p - BLNK (human)
Modsite: SDDFDSDyENPDEHS SwissProt Entrez-Gene
Orthologous residues
BLNK (human): Y72‑p, BLNK iso3 (human): , BLNK (mouse): Y72‑p, BLNK (rat): Y72‑p, BLNK (chicken): Y91‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Daudi (B lymphocyte), DT40 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Syk (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PLCG1 (human) Induces enzymatic activity, induced transcription, altered co-immunoprecipitation
NCK2 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
VAV1 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
Btk (human) Induces molecular association, regulation, enzymatic activity, induced co-immunoprecipitation
Comments:  Sites mutated alone and in combination (Y189,Y178and Y96) prevented binding of PLCG1 and mobization of Ca2+. For NF-AT transcriptional activity Y103,Y194 and Y205 residues were necessary.Tyrosine phosphoryation of BLNK induces MAPK activation., Tyrosine phosphoryation of BLNK is required for Ca2+ and MAPK activation.

Y84-p - BLNK (human)
Modsite: EHSDSEMyVMPAEEN SwissProt Entrez-Gene
Orthologous residues
BLNK (human): Y84‑p, BLNK iso3 (human): , BLNK (mouse): Y84‑p, BLNK (rat): Y84‑p, BLNK (chicken): Y103‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Daudi (B lymphocyte), DT40 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Syk (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
NCK2 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
PLCG1 (human) Induces enzymatic activity, induced transcription, altered co-immunoprecipitation
VAV1 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
Btk (human) Induces molecular association, regulation, enzymatic activity, induced co-immunoprecipitation
Comments:  Sites mutated alone and in combination (Y189,Y178and Y96) prevented binding of PLCG1 and mobization of Ca2+. For NF-AT transcriptional activity Y103,Y194 and Y205 residues were necessary.Tyrosine phosphoryation of BLNK induces MAPK activation., Tyrosine phosphoryation of BLNK is required for Ca2+ and MAPK activation.

Y96-p - BLNK (human)
Modsite: EENADDSyEPPPVEQ SwissProt Entrez-Gene
Orthologous residues
BLNK (human): Y96‑p, BLNK iso3 (human): , BLNK (mouse): Y96‑p, BLNK (rat): Y96‑p, BLNK (chicken): Y115‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Daudi (B lymphocyte), DT40 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Syk (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PLCG1 (human) Induces enzymatic activity, induced transcription, altered co-immunoprecipitation
NCK2 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
VAV1 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
Btk (human) Induces molecular association, regulation, enzymatic activity, induced co-immunoprecipitation
Comments:  Sites mutated alone and in combination (Y189,Y178and Y96) prevented binding of PLCG1 and mobization of Ca2+. For NF-AT transcriptional activity Y103,Y194 and Y205 residues were necessary.Tyrosine phosphoryation of BLNK induces MAPK activation., Tyrosine phosphoryation of BLNK is required for Ca2+ and MAPK activation.

Y178-p - BLNK (human)
Modsite: LLEDEADyVVPVEDN SwissProt Entrez-Gene
Orthologous residues
BLNK (human): Y178‑p, BLNK iso3 (human): , BLNK (mouse): Y178‑p, BLNK (rat): Y178‑p, BLNK (chicken): Y194‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Daudi (B lymphocyte), DT40 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Syk (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
NCK2 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
Btk (human) Induces molecular association, regulation, enzymatic activity, induced co-immunoprecipitation
PLCG1 (human) Induces enzymatic activity, induced transcription, altered co-immunoprecipitation
VAV1 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
Comments:  Sites mutated alone and in combination (Y189,Y178and Y96) prevented binding of PLCG1 and mobization of Ca2+. For NF-AT transcriptional activity Y103,Y194 and Y205 residues were necessary.Tyrosine phosphoryation of BLNK induces MAPK activation.

Y189-p - BLNK (human)
Modsite: VEDNDENyIHPtESS SwissProt Entrez-Gene
Orthologous residues
BLNK (human): Y189‑p, BLNK iso3 (human): , BLNK (mouse): Y189‑p, BLNK (rat): Y189‑p, BLNK (chicken): Y205‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site, peptide sequencing, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  lymphoma, B cell lymphoma, Burkitt's lymphoma
Relevant cell lines - cell types - tissues:  Daudi (B lymphocyte), DT40 (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Syk (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  transcription, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Btk (human) Induces molecular association, regulation, enzymatic activity, induced co-immunoprecipitation
VAV1 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
NCK2 (human) Induces molecular association, regulation, activity, induced co-immunoprecipitation
PLCG1 (human) Induces enzymatic activity, induced transcription, altered co-immunoprecipitation
Comments:  Sites mutated alone and in combination (Y189,Y178and Y96) prevented binding of PLCG1 and mobization of Ca2+. For NF-AT transcriptional activity Y103,Y194 and Y205 residues were necessary.Tyrosine phosphoryation of BLNK induces MAPK activation.

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
antigenic stimulation increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p